Nureca Limited
NURECA · 543264 · Healthcare · Medical Equipment & Supplies
- Market cap
- Rs 289 Cr
- P/E
- 70.44x
- P/B
- 1.60x
- 52W high / low
- Rs 376 / Rs 204
Our computed roe (2.31%) diverges from BSE's own published figure (1.13%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (2.83%) diverges from BSE's own published figure (6.02%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Nureca
Nureca Limited is listed on the NSE under the symbol NURECA and on the BSE under scrip code 543264. It is classified in the Healthcare sector, industry: Medical Equipment & Supplies. The company listed on 25 Feb 2021 and has a face value of Rs 10.
The latest available end-of-day price is Rs 302.9 (+0.80% on the day), for a market capitalisation of Rs 289 Cr. Trailing P/E is 70.44x and price-to-book is 1.60x. The 52-week range is Rs 204 to Rs 376. The latest price is 57% of the way from the 52-week low to the 52-week high.
Against the 13-company comparison set from the official BSE basic industry Medical Equipment & Supplies, its market capitalisation is 0.8 times the peer median of Rs 373 Cr, and its P/E of 70.44x compares with a peer median of 22.27x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Nureca Limited reported revenue of Rs 147 Cr and net profit of Rs 2.1 Cr, with a net margin of 1.42% and earnings per share of Rs 2.11 (consolidated statements).
Year-on-year change: revenue +27.00%; net profit +146.10%; EPS +148.24%. Three-year compound annual growth rate: revenue +9.40%; net profit not meaningful (a loss in one of the periods).
At the same date the balance sheet shows total assets of Rs 196 Cr, shareholders' equity of Rs 181 Cr, total debt of Rs 0.7 Cr, cash of Rs 1.5 Cr, a debt-to-equity ratio of 0.00 and operating cash flow of Rs 3.3 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 153 Cr, net income of Rs 4.3 Cr and a net margin of 2.83%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Nureca Limited's ownership is split: promoters 70.68%; foreign institutional investors (FIIs) 0.22%; domestic institutional investors (DIIs) 0.24%; retail and other shareholders 28.86%.
Compared with the filing for 30 Jun 2026: promoter holding +2.59 percentage points; FII holding +0.11 percentage points; DII holding 0.00 percentage points.
The same filing lists reported promoter pledge of 0.00% and 31,719 shareholders on record.
Recent filings and corporate actions
96 BSE corporate announcements were filed by Nureca Limited in the past twelve months; the most frequent category is "Company Update" (60). The most recent is "Copy of Newspaper Publication" (Company Update), filed on 22 Oct 2026.
The disclosed corporate-action timeline lists 2 entries: buyback (1), dividend (1). The latest is a buyback (Buy Back of Shares) with ex-date 12 Dec 2025.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Medical Equipment & Supplies. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Fischer Medical Ventures Limited | Rs 25.93 | Rs 1,697 Cr | Rs 373 Cr | Rs 29.8 Cr | 10.80x | 8.25% |
| Tarsons Products Limited | Rs 303.95 | Rs 1,617 Cr | Rs 468 Cr | Rs 11.1 Cr | — | 1.75% |
| Laxmi Dental Limited | Rs 177.37 | Rs 975 Cr | Rs 296 Cr | Rs 30.9 Cr | 31.34x | 13.67% |
| Hemant Surgical Industries Ltd | Rs 585 | Rs 850 Cr | — | — | 46.68x | — |
| Fabtech Technologies Limited | Rs 122.21 | Rs 543 Cr | Rs 414 Cr | Rs 35.6 Cr | 14.34x | 8.11% |
| Prevest Denpro Ltd | Rs 380.15 | Rs 456 Cr | — | — | 22.27x | — |
| Nureca LimitedThis company | Rs 302.9 | Rs 289 Cr | Rs 160 Cr | Rs 4.3 Cr | 70.44x | 2.31% |
| Earkart Ltd | Rs 116 | Rs 160 Cr | — | — | 32.31x | — |
| Choksi Asia Ltd | Rs 211.9 | Rs 121 Cr | Rs 48 Cr | Rs 5.2 Cr | 23.29x | 13.14% |
| Shree Pacetronix Ltd | Rs 174.75 | Rs 65.5 Cr | Rs 21.3 Cr | Rs 3.2 Cr | 19.68x | 8.58% |
| Amkay Products Ltd | Rs 53 | Rs 45.9 Cr | — | — | 19.85x | — |
| Royal Sense Ltd | Rs 70 | Rs 37.5 Cr | — | — | 12.43x | — |
| GKB Ophthalmics Limited | Rs 60.01 | Rs 30.2 Cr | Rs 153 Cr | Rs 5.5 Cr | 9.33x | 6.19% |
| Median | Rs 176.06 | Rs 373 Cr | Rs 296 Cr | Rs 11.1 Cr | 22.27x | 8.25% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Nureca
Same official industry (Medical Equipment & Supplies)
- Fischer Medical Ventures LimitedFISCHER · Market cap Rs 1,697 Cr
- Tarsons Products LimitedTARSONS · Market cap Rs 1,617 Cr
- Laxmi Dental LimitedLAXMIDENTL · Market cap Rs 975 Cr
- Hemant Surgical Industries LtdINE0GYI01028 · Market cap Rs 850 Cr
- Fabtech Technologies LimitedFABTECH · Market cap Rs 543 Cr
- Prevest Denpro LtdINE0GAO01018 · Market cap Rs 456 Cr
- Earkart LtdINE1A8F01035 · Market cap Rs 160 Cr
- Choksi Asia LtdINE865B01016 · Market cap Rs 121 Cr
Other Healthcare companies of a similar market capitalisation
- Vijaya Diagnostic Centre LimitedVIJAYA · Market cap Rs 15,066 Cr
- Jubilant Pharmova LimitedJUBLPHARMA · Market cap Rs 14,947 Cr
- Poly Medicure LimitedPOLYMED · Market cap Rs 14,818 Cr
- Indegene LimitedINDGN · Market cap Rs 14,272 Cr
- Natco Pharma LimitedNATCOPHARM · Market cap Rs 14,097 Cr
- Concord Biotech LimitedCONCORDBIO · Market cap Rs 12,874 Cr
- Rainbow Childrens Medicare LimitedRAINBOW · Market cap Rs 12,155 Cr
- Blue Jet Healthcare LimitedBLUEJET · Market cap Rs 8,735 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.